sandra susanibar adaniya

Assistant Professor

University of Pennsylvania

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Sandra Susanibar Adaniya is an Assistant Professor at the University of Pennsylvania, USA. Her research primarily focuses on multiple myeloma, particularly the effectiveness of novel therapies such as teclistamab and CAR T cell therapy. Dr. Adaniya's recent publications explore various aspects of treatment outcomes, disparities in care among racial and ethnic minorities, and the safety profiles of immunotherapeutic approaches for patients with multiple myeloma.

Articles (11)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

University of Pennsylvania

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

sandra susanibar adaniya

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma

Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment

Nontuberculous mycobacterial infections following teclistamab in multiple myeloma.

Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium

Age-related disparities in treatment and outcomes for newly diagnosed multiple myeloma: a population-based study

T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

High SOX2 expression is associated with poor survival in patients with newly diagnosed multiple myeloma

Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy

CAR T cell therapy for multiple myeloma: What have we learned?

Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy

2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management

Collaborators (7)

Alfred Garfall

Stefan Barta

Dan Vogl

Rahul Banerjee

Vivianna Van Deerlin

Qi Long

Adam Cohen

Make your next move.